je.st
news
Merck Completes Enrollment in Pivotal Phase 3 EPOCH Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimers Disease
2016-01-28 14:00:26| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. APECS Study Investigating Verubecestat in Patients with Prodromal Alzheimers Ongoing KENILWORTH, N.J. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today confirmed the completion of enrollment for the EPOCH trial, a Phase 2/3 randomized, placebo-controlled, parallel-group, double-blind study of verubecestat, formerly known as MK-8931, the companys investigational oral small molecule selective beta secretase (BACE1) inhibitor, in patients with mild-to-moderate Alzheimers disease (AD). The ongoing study commenced in November 2012, completed enrollment in the fourth quarter of 2015 and is estimated to reach primary trial completion in July 2017. Language: English read more
Tags: with
safety
trial
phase
Category:Biotechnology and Pharmaceuticals